Tabimorelin
Tabimorelin has been in phase II clinical trials by Novo Nordisk for the treatment of somatotropin deficiency. However, this research has been discontinued.
General Information
Update Date：2016-04-26
- Drug Name：
- Tabimorelin
- Research Code：
- NN-703; NNC-26-0703
- Trade Name：
- MOA：
- Growth hormone releasing factor agonist
- Indication：
- Growth hormone deficit
- Status：
- Phase Ⅱ (Discontinued)
- Company：
- Novo Nordisk (Originator)
- Sales：
- ATC Code：
Chemical Structure
Update Date：2016-01-06
|
Molecular Weight | 528.68 | ||||||||||||
| Formula | C32H40N4O3 | |||||||||||||
| CAS No. | 193079-69-5 (Tabimorelin); | |||||||||||||
| Chemical Name | D-Phenylalaninamide, N-[(2E)-5-amino-5-methyl-1-oxo-2-hexen-1-yl]-N-methyl-3-(2-naphthalenyl)-D-alanyl-N,Na-dimethyl- | |||||||||||||
| Tabimorelin （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||